Curaleaf Holdings, Inc. Annual Report Summary

Curaleaf Holdings, Inc., a major player in the global cannabis market, has just released its comprehensive annual report (a 40-F filing for foreign companies) for the fiscal year ending December 31, 2025. This crucial document details the company's financial performance and strategic shifts, offering investors a deep dive into its operations, profitability, and significant structural changes.

Business Overview

Curaleaf Holdings, Inc. stands as a leading international cannabis company, cultivating, processing, and distributing cannabis products for both medical and adult-use markets. As a vertically integrated multi-state operator (MSO) in the United States, Curaleaf manages its entire supply chain, from cultivation facilities and processing sites to a vast network of retail dispensaries. While maintaining a significant U.S. presence, the company also expands its international operations, particularly in European medical cannabis markets. Its diverse product portfolio includes flower, pre-rolls, vapes, edibles, and other cannabis-infused products, sold under various brands.

Financial Performance

• Revenue Dynamics: Curaleaf reported $1.27 billion in total revenue for the full year 2025. In the fourth quarter (Q4 2025), revenue reached $333 million, a modest 2% increase from $326.5 million in Q4 2024.
  • International Growth Engine: The international business emerged as a standout performer, generating $172.5 million for the full year 2025—a substantial 63% increase from $105.6 million in 2024. Q4 2025 international revenue grew to $51 million, up 65% from $31 million in Q4 2024. This robust growth resulted from expanded retail and wholesale operations and increased management fees.
  • U.S. Domestic Headwinds: In contrast, the U.S. domestic business saw revenue decline to $1.09 billion in 2025 from $1.23 billion in 2024. This downturn affected both retail and wholesale segments across the U.S., primarily due to persistent "double-digit price compression"—a third consecutive year of falling cannabis product prices—and intense market competition. As a vertically integrated multi-state operator, Curaleaf manages cultivation, processing, and distribution across various U.S. states.
• Profitability & Efficiency: Despite mixed revenue results, Curaleaf improved its operational efficiency. The adjusted gross profit margin for the full year 2025 rose to 50%, up from 48.4% in 2024. This improvement reflects better cost management in product manufacturing, even amidst declining prices.
• Net Loss Widens: Despite improved gross margins, Curaleaf continued to operate at a loss. The company reported a net loss of $201.9 million for the full year 2025. The adjusted net loss for 2025 reached $175.9 million, exceeding the $112.5 million adjusted loss in 2024. This widening loss, even with better gross margins, suggests increasing operating expenses (such as selling, general, and administrative costs, and research and development) and higher interest expenses are impacting the bottom line.

Financial Health and Liquidity

• Cash Position and Liquidity: Curaleaf generated strong cash, reporting $152 million from operations and $89 million in free cash flow (cash remaining after essential business investments) for the full year 2025. The company ended the year with a $101.6 million cash balance. A critical aspect of Curaleaf's liquidity is the U.S. Reorganization, which restricts cash flow between the parent company and its U.S. cannabis operations. This structure requires U.S. operations to be self-sufficient in their financing, potentially complicating future U.S. acquisitions or expansions.
• Debt Management: At year-end 2025, Curaleaf carried $548.7 million in outstanding debt. After year-end, the company successfully refinanced a significant portion by issuing $500 million in new senior secured notes due in 2029. These proceeds repaid existing debt, including notes due sooner in 2026, extending the company's debt maturity profile and providing greater financial flexibility. This refinancing, however, slightly increased the overall interest rate on some borrowings.
• Capital Investments: The company invested $63.4 million in capital expenditures during 2025, primarily for facility upgrades, automation, and opening new retail locations in key markets. These investments reflect ongoing expansion and operational enhancements.

Management Discussion and Analysis (MD&A) Highlights

• Key Factors Affecting Performance: Management noted that the U.S. domestic business faced significant headwinds, primarily from persistent "double-digit price compression"—a third consecutive year of falling cannabis product prices—and intense market competition, which led to declining U.S. revenue. Conversely, the international business served as a strong growth engine, driven by expanded retail and wholesale operations and increased management fees. Despite these revenue challenges, the company improved its adjusted gross profit margin through better cost management. However, increased operating expenses and higher interest expenses contributed to a widening net loss.
• Strategic Initiatives and Corporate Developments: A major strategic shift involved the TSX listing and subsequent U.S. Reorganization. On December 14, 2023, Curaleaf's Subordinate Voting Shares (SVS) began trading on the Toronto Stock Exchange (TSX). To comply with TSX rules for companies with U.S. cannabis operations, Curaleaf undertook a significant "Reorganization" of its U.S. business. This structural change transferred legal voting control of its U.S. cannabis operations (Curaleaf, Inc.) to an independent third-party investor for a nominal sum, while the parent company retained 99.9% of the economic value. This reorganization critically restricts cash flow between the parent company and its U.S. operations, requiring the U.S. business to be self-funding. Management emphasized completing the "Return to Our Roots" plan and transitioning to a "Built for Growth" strategy. This strategy focuses on organic growth by optimizing cultivation, refining product selection, strengthening brands, and pursuing strategic acquisitions.
• Operational Enhancements: Curaleaf expanded its retail footprint to 161 stores nationwide, opening new locations in Florida and Maine. It also launched new products like 'Anthem Bold' pre-rolls and 'Dark Heart' premium flower, enhancing its brand portfolio. The company actively managed its portfolio, including strategic acquisitions (e.g., Northern Green Canada, Curaleaf Poland, DarkHeart) to expand market reach and product offerings. It also disposed of non-core or underperforming assets in markets like Missouri, California, Colorado, Oregon, Michigan, Kentucky, and certain non-cannabis UK operations, aiming to streamline its focus and improve profitability.

Future Outlook and Strategy

• Strategic Direction: Curaleaf has transitioned from its "Return to Our Roots" plan to a "Built for Growth" strategy. CEO Boris Jordan indicates this strategy centers on driving organic growth by optimizing cultivation practices, refining product selection, strengthening brand portfolios, and pursuing strategic, value-accretive acquisitions that align with market expansion goals. The company aims to enhance operational efficiencies and leverage its vertically integrated model to improve profitability.
• Market Focus: The company plans to continue expanding its international footprint, particularly in medical cannabis markets, which show robust growth. In the U.S., it will focus on navigating the competitive landscape and price compression by optimizing existing operations and selectively pursuing opportunities, while adhering to capital restrictions imposed by the U.S. Reorganization.
• Financial Guidance: The company's ability to fund future U.S. growth and acquisitions will be significantly influenced by the self-funding requirements of its U.S. operations due to the Reorganization.

Competitive Position

Curaleaf Holdings, Inc. holds a significant competitive position as one of the largest vertically integrated multi-state operators (MSOs) in the U.S. cannabis industry, complemented by a growing international presence. Its competitive advantages include:

• Scale and Reach: A vast retail footprint of 161 dispensaries nationwide, coupled with extensive cultivation and processing capabilities across multiple states, provides significant operational scale and market penetration.
• Brand Portfolio: The company boasts a diverse portfolio of established brands, including 'Select,' a leading U.S. vape brand. New product launches like 'Anthem Bold' pre-rolls and 'Dark Heart' premium flower cater to various consumer segments. Internationally, Curaleaf innovates with medical devices such as the 'QMID' in the UK and Germany.
• Vertical Integration: Its seed-to-sale model allows greater control over product quality, supply chain efficiency, and cost management—crucial in a competitive and price-sensitive market.
• International Expansion: Early mover advantage and strategic investments in key international medical cannabis markets (e.g., Europe) differentiate Curaleaf from many U.S.-centric competitors.

Despite these strengths, the company operates in a highly competitive environment, particularly in the U.S. It faces intense competition from both established players and new entrants, contributing to price compression and market share pressures.

Risk Factors

Investors should be aware of several significant risks:

• Regulatory & Legal Risks: The federal illegality of cannabis in the U.S. continues to pose substantial challenges, including limited access to traditional banking services, restrictions on interstate commerce, and a heavy tax burden (IRS Code Section 280E). State-level regulatory changes or licensing issues could also impact operations.
• Operational Risks: Persistent "double-digit price compression" in the U.S. market directly impacts revenue and profitability. Supply chain disruptions, product quality control, and intense competition from both established players and new entrants remain ongoing concerns.
• Financial Risks: Despite positive cash flow, the company's net loss and increased interest rates on its debt could strain future profitability. The inability to transfer cash between the parent company and its U.S. operations creates distinct liquidity and capital-raising challenges for the U.S. business, potentially hindering its ability to fund growth or respond to market opportunities.
• Structural Risks (U.S. Reorganization): The lack of direct voting control over U.S. operations introduces a unique governance risk. While safeguards protect the parent company's economic interest and prevent major changes to the U.S. business without consent, the long-term implications of this separation on strategic alignment and operational agility warrant close monitoring.

In summary, Curaleaf presents a complex investment profile. Its international segment drives robust growth, and the company improves operational efficiency. However, the U.S. domestic business faces significant headwinds from price compression and competition, contributing to a widening net loss despite positive cash flow. The innovative U.S. Reorganization addresses TSX listing requirements but introduces critical structural limitations on capital allocation. Investors should closely monitor the execution of the "Built for Growth" strategy, the evolution of the U.S. cannabis market, and how the company navigates the unique financial and operational constraints its new corporate structure imposes.